Academic detailing outreach to primary care providers significantly increases prescribing rates of FDA-approved medications for alcohol use disorder (naltrexone, topiramate, disulfiram) among veterans.
Osmind presented comparative efficacy data for intravenous ketamine versus nasal esketamine at ASCP, offering clinical insights relevant to treatment-resistant depression management.
A case report demonstrates that combining diazepam and aripiprazole effectively treats catatonic stupor in a high-risk patient with pulmonary embolism who could not undergo electroconvulsive therapy.
Nervigen's roluperidone, a potential treatment for schizophrenia negative symptoms, is awaiting pivotal clinical data expected in 2027.
Autobahn Therapeutics advances a thyroid hormone receptor agonist for bipolar depression into pivotal trials following positive Phase 2 results.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Jun 05 – Jun 06)
- Consider the thyroid hormone receptor agonist from Autobahn Therapeutics as a novel mechanism of interest for bipolar depression once pivotal trial results become available.
- Monitor the development of Nervigen's roluperidone for schizophrenia negative symptoms, with pivotal data expected in 2027 to potentially fill an unmet treatment gap.
- Implement academic detailing initiatives in primary care settings to significantly increase the prescribing rates of FDA-approved alcohol use disorder medications like naltrexone and topiramate.
- Utilize the combination of diazepam and aripiprazole as a viable pharmacologic strategy for catatonic stupor when electroconvulsive therapy is contraindicated or unavailable.
- Review comparative efficacy data between intravenous ketamine and nasal esketamine to inform treatment-resistant depression management decisions based on patient access and preference.